These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 16238905)

  • 1. Differences in compliance patterns across the selective serotonin reuptake inhibitors (SSRIs).
    Keene MS; Eaddy MT; Mauch RP; Regan TS; Shah M; Chiao E
    Curr Med Res Opin; 2005 Oct; 21(10):1651-8. PubMed ID: 16238905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differences in total medical costs across the SSRIs for the treatment of depression and anxiety.
    Sheehan DV; Eaddy MT; Shah MB; Mauch RP
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S354-61. PubMed ID: 16236017
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to paroxetine CR compared with paroxetine IR in a Medicare-eligible population with anxiety disorders.
    Keene MS; Eaddy MT; Nelson WW; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S362-9. PubMed ID: 16236018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Persistence, switching, and discontinuation rates among patients receiving sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Harrison D
    Pharmacotherapy; 2005 May; 25(5):660-7. PubMed ID: 15899727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery.
    Mead GE; Hsieh CF; Lee R; Kutlubaev MA; Claxton A; Hankey GJ; Hackett ML
    Cochrane Database Syst Rev; 2012 Nov; 11(11):CD009286. PubMed ID: 23152272
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of Bayesian net benefit regression model to examine the impact of generic drug entry on the cost effectiveness of selective serotonin reuptake inhibitors in elderly depressed patients.
    Shih YC; Bekele NB; Xu Y
    Pharmacoeconomics; 2007; 25(10):843-62. PubMed ID: 17887806
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative assessment of adherence measures and resource use in SSRI/SNRI-treated patients with depression using second-generation antipsychotics or L-methylfolate as adjunctive therapy.
    Wade RL; Kindermann SL; Hou Q; Thase ME
    J Manag Care Pharm; 2014 Jan; 20(1):76-85. PubMed ID: 24372461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A claims analysis comparing citalopram with sertraline as initial pharmacotherapy for a new episode of depression: impact on depression-related treatment charges.
    McLaughlin TP; Eaddy MT; Grudzinski AN
    Clin Ther; 2004 Jan; 26(1):115-24. PubMed ID: 14996524
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of first refill rates among users of sertraline, paroxetine, and citalopram.
    Mullins CD; Shaya FT; Meng F; Wang J; Bron MS
    Clin Ther; 2006 Feb; 28(2):297-305; discussion 296. PubMed ID: 16678651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. What are the risks associated with different Selective Serotonin Re-uptake Inhibitors (SSRIs) to treat depression and anxiety in pregnancy? An evaluation of current evidence.
    Womersley K; Ripullone K; Agius M
    Psychiatr Danub; 2017 Sep; 29(Suppl 3):629-644. PubMed ID: 28953843
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Implications of an SSRI generic step therapy pharmacy benefit design: an economic model in anxiety disorders.
    Panzer PE; Regan TS; Chiao E; Sarnes MW
    Am J Manag Care; 2005 Oct; 11(12 Suppl):S370-9. PubMed ID: 16236019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a retrospective claims database analysis of differences in antidepressant treatment persistence associated with escitalopram and other selective serotonin reuptake inhibitors in the United States.
    Esposito D; Wahl P; Daniel G; Stoto MA; Erder MH; Croghan TW
    Clin Ther; 2009 Mar; 31(3):644-56. PubMed ID: 19393855
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prescribing of selective serotonin reuptake inhibitors, anxiolytics, and sedative-hypnotics by general practitioners in The Netherlands: a multivariate analysis.
    Pathiyal A; Hylan TR; Jones JK; Davtian D; Sverdlov L; Keyser M
    Clin Ther; 1997; 19(4):798-810. PubMed ID: 9377622
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective Serotonin Reuptake Inhibitor Use and Risk of Arrhythmia: A Nationwide, Population-Based Cohort Study.
    Lin YT; Lu TS; Hansen RA; Wang CC
    Clin Ther; 2019 Jun; 41(6):1128-1138.e8. PubMed ID: 31178037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypobaric hypoxia exposure in rats differentially alters antidepressant efficacy of the selective serotonin reuptake inhibitors fluoxetine, paroxetine, escitalopram and sertraline.
    Kanekar S; Sheth CS; Ombach HJ; Olson PR; Bogdanova OV; Petersen M; Renshaw CE; Sung YH; D'Anci KE; Renshaw PF
    Pharmacol Biochem Behav; 2018 Jul; 170():25-35. PubMed ID: 29738811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system.
    Ozminkowski RJ; Hylan TR; Melfi CA; Meneades LM; Crown WH; Croghan TW; Robinson RL
    Clin Ther; 1998; 20(4):780-96. PubMed ID: 9737837
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differences in medication adherence and healthcare resource utilization patterns: older versus newer antidepressant agents in patients with depression and/or anxiety disorders.
    Sheehan DV; Keene MS; Eaddy M; Krulewicz S; Kraus JE; Carpenter DJ
    CNS Drugs; 2008; 22(11):963-73. PubMed ID: 18840035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis.
    Kennedy SH; Andersen HF; Lam RW
    J Psychiatry Neurosci; 2006 Mar; 31(2):122-31. PubMed ID: 16575428
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the Effect of Selective Serotonin Reuptake Inhibitors in the Prevention of Post-Acute Sequelae of COVID-19.
    Sidky H; Sahner DK; Girvin AT; Hotaling N; Michael SG; Gersing K
    medRxiv; 2023 Feb; ():. PubMed ID: 36380766
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.